Nicotinamide and its effects on endothelial dysfunction and secretion of antiangiogenic factors by primary human placental cells and tissues
Fiona Brownfoot, Natalie Binder, Roxanne Hastie, Alesia Harper, Sally Beard, Laura Tuohey, Emerson Keenan, Stephen Tong, Natalie Hannan
PLACENTA | W B SAUNDERS CO LTD | Published : 2021
Preeclampsia is a serious pregnancy complication associated with elevated antiangiogenic markers and endothelial dysfunction. Recently nicotinamide (vitamin B3) was shown to reduce high blood pressure and proteinuria in mice models of the disease. Using primary human pregnancy tissue we show nicotinamide did not change antiangiogenic factor secretion including soluble fms-like tyrosine kinase 1 or soluble endoglin from primary cytotrophoblasts and placental explants. Furthermore, it did not reverse markers of endothelial dysfunction. Therefore, we did not demonstrate an effect of nicotinamide on reducing markers of preeclampsia from primary human placental tissues and vascular cells.
Related Projects (1)
Awarded by NHMRC Early Career Fellowship
Awarded by NHMRC
FB was supported by a NHMRC Early Career Fellowship (#1142636) and a Norman Beischer Medical Research Foundation Fellowship grant. The NHMRC also provided salary support to ST (#1136418) and NJH (#1146128). The funders had no role in study design, data collection, analysis, decision to publish or the preparation of the manuscript.